Gelonghui July 12th 丨Kehua Biotech (002022.SZ) announced its 2023 semi-annual results forecast. Net profit for the reporting period attributable to shareholders of listed companies was 19 million yuan to 26 million yuan, down 44.00%-59.08% from the same period last year; net profit profit after deducting non-recurring profit and loss was 200,000 yuan to 7 million yuan, down 84.37%-100.00% from the same period last year; basic earnings per share profit of 0.0369 yuan/share — 0.0506 yuan/share.

During the reporting period, the company's continuous increase in R&D investment led to an increase in R&D expenses; at the same time, the company made asset impairment preparations for related assets that may be at risk of impairment. Non-recurring profit and loss for the reporting period mainly included interest income on bank structured deposits and government subsidies.